Abstract
Background: To study the protective effect of BMSC overexpressing SDF-1α on myocardial ischemia/reperfusion (I/R), to improve the limitation that only part of BMSC is recruited to the site of myocardial injury in the treatment of ischemic heart disease. It provides a new scheme for stem cell therapy for clinical treatment of reperfusion injury.Methods: Collect blood samples from PCI patients and healthy individuals to detect PMN and SDF-1α expression; Construction of BMSC overexpressing SDF-1α (oe-SDF-1α); In the case of no intervention or intervention by BMSC respectively, cell level: the migration ability of PMN to hypoxia/reoxygenation (H/R) cardiomyocytes and the expression of SDF-1α, CXCR4, apoptosis, oxidative stress and other indicators of cardiomyocytes were detected; In vivo level: PMN, SDF-1α, CXCR4, oxidative stress and inflammatory factor levels were detected in I/R mice. And carry out statistical analysis.Results: ① In the clinic, compared with the control group, the expression levels of SDF-1α and PMN in the blood of PCI patients increased. ② Under H/R conditions, cardiomyocytes express and secrete SDF-1α, activate PMN migration and infiltration mediated by SDF-1/CXCR4 signal pathway, promote cardiomyocyte apoptosis and increase the level of oxidative stress; oe-SDF-1α has a stronger ability to migrate to H/R cardiomyocytes and has more repair ability than BMSC.It is more suitable as a tool cell for stem cell therapy. ③ The expression levels of SDF-1α and PMN are increased in I/R mice. oe-SDF-1α can reduce the ability of PMN to reside to the damaged part of myocardial tissue significantly, thereby reducing myocardial tissue damage, oxidative stress, inflammatory factor levels in I/R mice. Conclusions: The SDF-1/CXCR4 biological axis not only plays an important role in BMSC migration, but also helps to enhance the therapeutic effect of BMSC-based therapy. Oe-SDF-1α has a more repairing effect on reducing cell damage caused by PMN, and can be used as a new type of cell for the treatment of IRI.
Stem Cell Therapy for Intestinal Ischemia-Reperfusion: Current State and Perspectives
